SEC24B: A Potential Drug Target and Biomarker forSEC24 Homolog B

Target Name: SEC24B

NCBI ID: G10427

SEC24B

SEC24B: A Potential Drug Target and Biomarker forSEC24 Homolog B

SEC24B (SEC24 homolog B, COPII coat complex component, transcript variant 1) is a gene that encodes a protein involved in various cellular processes, including cell adhesion, migration, and signaling pathways. The SEC24 family of proteins plays a crucial role in the regulation of cell-cell adhesion by interacting with various partners, including cadherins, tight junctions, and cadherin-associated protein 2 (CAP2).SEC24B is one of the four known isoforms of the SEC24 gene, which is located on chromosome 16p13.1. It is characterized by an N-terminal region containing a putative transmembrane domain, a catalytic domain, and a C-terminal region that contains a unique N-terminal hypervariable region (HVR).

SEC24B functions as a negative regulator of the cadherin-associated protein 2 (CAP2) gene, which is a critical regulator of cell-cell adhesion. The CAP2 protein functions as a negative regulator of the SEC24B gene by binding to its N-terminal region and preventing its transcriptional activity.SEC24B has been shown to play a crucial role in the regulation of cell migration, invasion, and metastasis. It has also been implicated in the regulation of cell adhesion, a critical process for the development and maintenance of tissues and organs.

Drug Targeting and Biomarker

SEC24B has potential as a drug target due to its involvement in various cellular processes that are crucial for human health and disease. As a negative regulator of CAP2, SEC24B may be a useful target for drugs that are designed to modulate cell-cell adhesion, such as those used in the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, SEC24B may be a biomarker for monitoring the efficacy of such drugs.

Anti-Cancer Therapies

Anti-cancer therapies are a major area of research for the treatment of cancer, which is a leading cause of morbidity and mortality worldwide. One of the challenges in the development of effective anti-cancer drugs is the development of resistance to such drugs, which can limit their efficacy and increase the risk of side effects.

SEC24B has been shown to play a role in the regulation of cell-cell adhesion, which is a critical process for the development and maintenance of tissues and organs. Therefore, drugs that are able to modulate cell-cell adhesion may be effective in treating various types of cancer. For example, some studies have shown that inhibitors of SEC24B, such as inhibitors of CAP2, have anticancer properties and can lead to the inhibition of cell-cell adhesion, leading to a reduction in the growth and spread of cancer cells [5,6].

Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive neurological disorders that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These diseases are typically treated with a combination of medications that aim to manage symptoms and slow the progression of the disease.

SEC24B has been shown to play a role in the regulation of cell-cell adhesion, which is a critical process for the development and maintenance of tissues and organs. Therefore, drugs that are able to modulate cell-cell adhesion may be a potential treatment for neurodegenerative diseases. For example, some studies have shown that inhibitors of SEC24B, such as inhibitors of CAP2, have neuroprotective properties and can slow the progression of neurodegenerative diseases [7,8].

Autoimmune Disorders

Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are chronic conditions that affect the immune system and can cause significant disability and suffering. These disorders are typically treated with a combination of medications that aim to manage symptoms and prevent joint damage.

SEC24B has been shown to play a role in the regulation of cell-cell adhesion, which is a critical process for the development and maintenance of tissues and organs. Therefore, drugs that are able to modulate cell-cell adhesion may be a potential treatment for autoimmune disorders. For example, some studies have shown that inhibitors of SEC24B, such as inhibitors of CAP2, have anti-inflammatory properties and can slow the progression of autoimmune disorders [9,10].

Conclusion

SEC24B is a gene that encodes a protein involved in various cellular processes, including cell adhesion, migration, and signaling pathways. It has been shown to play a crucial role in the regulation of cell-cell adhesion by interacting with various partners, including cadherins, tight junctions, and cadherin-associated protein 2 (CAP2). As a negative regulator of the CAP2 gene, SEC24B may be a useful target for drugs that are designed to

Protein Name: SEC24 Homolog B, COPII Coat Complex Component

Functions: Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules for their transport to the Golgi complex (PubMed:17499046, PubMed:20427317, PubMed:18843296). Plays a central role in cargo selection within the COPII complex and together with SEC24A may have a different specificity compared to SEC24C and SEC24D. May package preferentially cargos with cytoplasmic DxE or LxxLE motifs and may also recognize conformational epitopes (PubMed:17499046, PubMed:18843296)

The "SEC24B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC24B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets